Table 2.

Demographic and clinical characteristics according to the development of AKI by the KDIGO definition during hospitalization

CharacteristicNo AKI All AKI StagesaStage 1Stage 2Stage 3
Participants, n26,122584841481001699
Demographic data
 Age, yr50 (35–66)64 (52–75)64 (53–75)62 (52–72)64 (52–74)
 Men, %31.950.450.346.057.1
 Race, %
 White71.579.479.679.678.0
 Black11.18.68.58.310.2
 Hispanic7.85.25.54.54.7
 Other9.76.86.57.67.2
Laboratory values on admissionb
 Serum creatinine, mg/dl0.8 (0.7–1.0)1.0 (0.8–1.5)1.0 (0.7–1.3)1.1 (0.8–1.5)1.9 (1.0–3.6)
 Hemoglobin, g/dl11.8 (10.4–13.0)11.1 (9.7–12.7)11.2 (9.9–12.7)11.1 (9.7–12.8)10.3 (8.9–11.8)
 White blood cell count, 1000/μl8.7 (6.5–11.6)8.9 (6.3–12.8)8.7 (6.3–12.4)9.6 (6.5–14.1)9.3 (5.9–14.3)
 Platelet count, 1000/μl245 (193–311)234 (167–315)236 (172–315)233 (158–319)220 (117–310)
 BUN, mg/dl13 (10–18)19 (13–31)18 (12–27)20 (14–33)35 (19–63)
 Sodium, mmol/L137 (135–139)137 (134–139)137 (134–139)137 (133–139)136 (133–139)
 CO2, mmol/L25 (23–27)24 (22–27)25 (22–27)24 (21–27)22 (19–26)
 Albumin, g/dl3.7 (3.3–4.0)3.5 (3.0–3.9)3.6 (3.1–4.0)3.4 (2.9–3.9)3.2 (2.8–3.7)
 Total bilirubin, mg/dl0.4 (0.3–0.6)0.5 (0.3–0.8)0.5 (0.3–0.7)0.5 (0.3–0.8)0.5 (0.3–1.0)
  • Results are presented as medians with interquartile ranges or column percentages. KDIGO, Kidney Disease Improving Global Outcomes.

  • a P<0.001 for all comparisons between patients with AKI and without AKI.

  • b The following indicate the laboratory values that were missing in patients without AKI and with AKI, respectively: hemoglobin, 31.1% and 1.4%; white blood cell count, 31.1% and 1.4%; platelet count, 31.1% and 1.4%; BUN, 30.5% and 1.1%; sodium, 33.7% and 1.5%; CO2, 33.7% and 1.5%; albumin, 62.4% and 26.1%; total bilirubin, 62.8% and 26.9%; and serum creatinine, 28.5% and 0.0%.